Randomized trial on mindfulness training for smokers targeted to a disadvantaged population.
Abstract
We report the results of a randomized trial comparing a novel smoking cessation treatment
Mindfulness Training for Smokers (MTS) to a usual care therapy (Controls), which included
the availability of a tobacco quit line and nicotine patches. Data were collected
from 196 low socioeconomic status smokers in 2010-2011 in Madison, Wisconsin. Participants
were randomized to either MTS or a telephonic quit line. The primary outcome was 6-month
smoking abstinence measured by carbon monoxide breath testing and Time-Line Follow-Back.
Among treatment initiators (randomized participants who participated in the intervention),
abstinence rates were significantly different between the MTS (38.7%) and control
(20.6%, p = .05) groups. Study limitations are also discussed. Results suggest that
further study is warranted.
Type
Journal articleSubject
AdultFemale
Humans
Male
Middle Aged
Mindfulness
Secondary Prevention
Smoking
Smoking Cessation
Tobacco Use Disorder
Treatment Outcome
Vulnerable Populations
Permalink
https://hdl.handle.net/10161/11684Published Version (Please cite this version)
10.3109/10826084.2013.770025Publication Info
Davis, James M; Goldberg, Simon B; Anderson, Maggie C; Manley, Alison R; Smith, Stevens
S; & Baker, Timothy B (2014). Randomized trial on mindfulness training for smokers targeted to a disadvantaged population.
Subst Use Misuse, 49(5). pp. 571-585. 10.3109/10826084.2013.770025. Retrieved from https://hdl.handle.net/10161/11684.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
James Davis
Associate Professor of Medicine
Dr. James Davis is a practicing physician of Internal Medicine, and serves as the
Medical Director for Duke Center for Smoking Cessation, Director of the Duke Smoking
Cessation Program and Co-Director of the Duke-UNC Tobacco Treatment Specialist Credentialing
Program. His research focuses on development of new pharmaceutical treatments for
smoking cessation. He is principal investigator on several trials including a study
on “adaptive” smoking cessation and several trials

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info